Indivior Can Split IP, Antitrust Claims In Suboxone Fight
A New Jersey federal judge agreed Tuesday to split patent infringement and antitrust allegations in the legal battle between Indivior Inc. and generic pharmaceutical companies over opioid addiction treatment Suboxone, ruling...To view the full article, register now.
Already a subscriber? Click here to view full article